Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin-piperaquine for persistent PCR-positive mild or common COVID-19 after hydroxychloroquine and arbidol
ChiCTR2000032915Phase 4Recruiting
- Sponsor
- Hongqi Hospital Affiliated to Mudangjiang Medical University
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin + piperaquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hongqi Hospital Affiliated to Mudangjiang Medical University. Primary endpoints: Tolerance, SARS-CoV-2 viral load and 11 more. Started May 2020; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000032915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032915.